Amit Rakhit, MD, Chief Medical and Portfolio Officer at Ovid Therapeutics, discusses how his company values working with patient groups.

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome, and recently completed a Phase 1 trial in adolescents with Angelman and Fragile X syndrome.